{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"autosomal-systemic-lupus-erythematosus-type-16","columns":[{"gene":"","key":"population-64db81b5979054bd440c","label":"Systemic lupus erythematosus 16","mondoId":"MONDO:0013743","onsetQualifier":null,"originColumnKey":"MONDO:0013743/OMIM:614420","originalViews":[{"key":"MONDO:0013743/OMIM:614420","label":"Systemic lupus erythematosus 16","scopeLabel":"OMIM:614420","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["0122c0244d08679c928950ef21c368cbab9f9203f443a4f0fccf26596a7b1254","055f5351750b89da58f7ccc52abad3c0d36fa3b9175e3a4b38369742c8996d20","220ae750ef7e2aeeeea089846cb7b6990b91d8d8e6e155f3aad4739bf4813f9f","42dfa64c39e57bf74621f6cbd8c17a5ed7cab21c8a3cfa90a9659434a5a68aec","61ede351b1a91907154b1f6d10ef537dc16213622b36b7f2a24573eec2e89a5c","65c5277acf9c3746a4cd556a1e4357216708727ac817cb51c5ff448386e96843","fab86804667bebb4003ec526a4eb3859730de465ebc9cbdfee4f82da230c1073"],"recordQualifiers":{},"scopeLabel":"OMIM:614420","sourceIds":["OMIM:614420"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-64db81b5979054bd440c"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0020151","HP:0003493","HP:0005421","HP:0045042","HP:0033726","HP:0032229","HP:0002725"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":7,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":7,"sourceGroups":{"published":7}},"features":[{"hpoId":"HP:0020151","label":"Anti-dsDNA antibody positivity","primary":true},{"hpoId":"HP:0003493","label":"Antinuclear antibody positivity","primary":true},{"hpoId":"HP:0005421","label":"Decreased circulating complement C3 concentration","primary":true},{"hpoId":"HP:0045042","label":"Decreased circulating complement C4 concentration","primary":true},{"hpoId":"HP:0033726","label":"Lupus nephritis","primary":true},{"hpoId":"HP:0032229","label":"Perinuclear antineutrophil antibody positivity","primary":true},{"hpoId":"HP:0002725","label":"Systemic lupus erythematosus","primary":true}],"ledeHtml":"Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body&#x27;s own tissues and organs. About a third of people with SLE develop kidney disease (nephritis). Heart problems may also occur in SLE, including inflammation of the sac-like membrane around the heart (pericarditis) and abnormalities of the heart valves, which control blood flow in the heart. Heart disease caused by fatty buildup in the blood vessels (atherosclerosis), which is very common in the general population, is even more common in people with SLE. The inflammation characteristic of SLE can also damage the nervous system, and may result in abnormal sensation and weakness in the limbs (peripheral neuropathy); seizures; stroke; and difficulty processing, learning, and remembering information (cognitive impairment). Anxiety and depression are also common in SLE. People with SLE have episodes in which the condition gets worse (exacerbations) and other times when it gets better (remissions). Overall, SLE gradually gets worse over time, and damage to the major organs of the body can be life-threatening. SLE may first appear as extreme tiredness (fatigue), a vague feeling of discomfort or illness (malaise), fever, loss of appetite, and weight loss. Most affected individuals also have joint pain, typically affecting the same joints on both sides of the body, and muscle pain and weakness. Skin problems are common in SLE. A characteristic feature is a flat red rash across the cheeks and bridge of the nose, called a &#x27;butterfly rash&#x27; because of its shape. The rash, which generally does not hurt or itch, often appears or becomes more pronounced when exposed to sunlight. Other skin problems that may occur in SLE include calcium deposits under the skin (calcinosis), damaged blood vessels (vasculitis) in the skin, and tiny red spots called petechiae. Petechiae are caused by a shortage of cells involved in clotting (platelets), which leads to bleeding under the skin. Affected individuals may also have hair loss (alopecia) and open sores (ulcerations) in the moist lining (mucosae) of the mouth, nose, or, less commonly, the genitals.","mondoId":"MONDO:0013743","node":{"canonicalSlug":"autosomal-systemic-lupus-erythematosus-type-16","comparisons":[{"documentSha256":"8e00e4ccc81b9964df7eaddcb32dd1f03cfb04766bc3f1e0b858e3bcf67e0930","key":"legacy-systemic-lupus-erythematosus","kind":"legacy","label":"systemic lupus erythematosus","memberIds":["MONDO:0007915","MONDO:0013743","MONDO:0019725","MONDO:0859083","MONDO:1060185"],"mondoId":"MONDO:0007915","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/systemic-lupus-erythematosus.8e00e4ccc81b9964df7eaddcb32dd1f03cfb04766bc3f1e0b858e3bcf67e0930.json"},{"documentSha256":"b48e58bd60704a34abb6d4fd491713ca86b4cca0afdcaa81135e4e41c0f83155","key":"expanded-systemic-lupus-erythematosus","kind":"expanded","label":"systemic lupus erythematosus","memberIds":["MONDO:0007915","MONDO:0013743","MONDO:0018360","MONDO:0019725","MONDO:0043985","MONDO:0044113","MONDO:0859083","MONDO:1060174","MONDO:1060176","MONDO:1060185"],"mondoId":"MONDO:0007915","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-b48e58bd60704a34abb6.b48e58bd60704a34abb6d4fd491713ca86b4cca0afdcaa81135e4e41c0f83155.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Autosomal systemic lupus erythematosus type 16","originalSourceId":"ORPHA:300345","paragraphs":["Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs. About a third of people with SLE develop kidney disease (nephritis). Heart problems may also occur in SLE, including inflammation of the sac-like membrane around the heart (pericarditis) and abnormalities of the heart valves, which control blood flow in the heart. Heart disease caused by fatty buildup in the blood vessels (atherosclerosis), which is very common in the general population, is even more common in people with SLE. The inflammation characteristic of SLE can also damage the nervous system, and may result in abnormal sensation and weakness in the limbs (peripheral neuropathy); seizures; stroke; and difficulty processing, learning, and remembering information (cognitive impairment). Anxiety and depression are also common in SLE. People with SLE have episodes in which the condition gets worse (exacerbations) and other times when it gets better (remissions). Overall, SLE gradually gets worse over time, and damage to the major organs of the body can be life-threatening. SLE may first appear as extreme tiredness (fatigue), a vague feeling of discomfort or illness (malaise), fever, loss of appetite, and weight loss. Most affected individuals also have joint pain, typically affecting the same joints on both sides of the body, and muscle pain and weakness. Skin problems are common in SLE. A characteristic feature is a flat red rash across the cheeks and bridge of the nose, called a 'butterfly rash' because of its shape. The rash, which generally does not hurt or itch, often appears or becomes more pronounced when exposed to sunlight. Other skin problems that may occur in SLE include calcium deposits under the skin (calcinosis), damaged blood vessels (vasculitis) in the skin, and tiny red spots called petechiae. Petechiae are caused by a shortage of cells involved in clotting (platelets), which leads to bleeding under the skin. Affected individuals may also have hair loss (alopecia) and open sores (ulcerations) in the moist lining (mucosae) of the mouth, nose, or, less commonly, the genitals."],"rawAttribution":"MONDO:0013743","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:42:22Z","upstream":"ORPHA:300345","url":"https://rarediseases.info.nih.gov/diseases/17368"},"ownColumnKeys":["population-64db81b5979054bd440c"],"publication":"published","relationships":[{"kind":"parent","label":"systemic lupus erythematosus","mondoId":"MONDO:0007915","slug":"systemic-lupus-erythematosus"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"0122c0244d08679c928950ef21c368cbab9f9203f443a4f0fccf26596a7b1254","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"17/17","hpo_id":"HP:0045042","is_excluded":false,"label":"Decreased circulating complement C4 concentration","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"055f5351750b89da58f7ccc52abad3c0d36fa3b9175e3a4b38369742c8996d20","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"17/17","hpo_id":"HP:0002725","is_excluded":false,"label":"Systemic lupus erythematosus","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"220ae750ef7e2aeeeea089846cb7b6990b91d8d8e6e155f3aad4739bf4813f9f","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"11/17","hpo_id":"HP:0032229","is_excluded":false,"label":"Perinuclear antineutrophil antibody positivity","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"42dfa64c39e57bf74621f6cbd8c17a5ed7cab21c8a3cfa90a9659434a5a68aec","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"11/17","hpo_id":"HP:0033726","is_excluded":false,"label":"Lupus nephritis","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"61ede351b1a91907154b1f6d10ef537dc16213622b36b7f2a24573eec2e89a5c","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"16/17","hpo_id":"HP:0020151","is_excluded":false,"label":"Anti-dsDNA antibody positivity","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"65c5277acf9c3746a4cd556a1e4357216708727ac817cb51c5ff448386e96843","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"17/17","hpo_id":"HP:0003493","is_excluded":false,"label":"Antinuclear antibody positivity","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"fab86804667bebb4003ec526a4eb3859730de465ebc9cbdfee4f82da230c1073","raw":{"aspect":"P","body_system":"immune","disease_id":"OMIM:614420","disease_name":"Systemic lupus erythematosus 16","evidence":"PCS","frequency_raw":"17/17","hpo_id":"HP:0005421","is_excluded":false,"label":"Decreased circulating complement C3 concentration","onset_id":null,"reference":"PMID:22019780","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17368\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0013743\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>ORPHA:300345</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body&#x27;s own tissues and organs. About a third of people with SLE develop kidney disease (nephritis). Heart problems may also occur in SLE, including inflammation of the sac-like membrane around the heart (pericarditis) and abnormalities of the heart valves, which control blood flow in the heart. Heart disease caused by fatty buildup in the blood vessels (atherosclerosis), which is very common in the general population, is even more common in people with SLE. The inflammation characteristic of SLE can also damage the nervous system, and may result in abnormal sensation and weakness in the limbs (peripheral neuropathy); seizures; stroke; and difficulty processing, learning, and remembering information (cognitive impairment). Anxiety and depression are also common in SLE. People with SLE have episodes in which the condition gets worse (exacerbations) and other times when it gets better (remissions). Overall, SLE gradually gets worse over time, and damage to the major organs of the body can be life-threatening. SLE may first appear as extreme tiredness (fatigue), a vague feeling of discomfort or illness (malaise), fever, loss of appetite, and weight loss. Most affected individuals also have joint pain, typically affecting the same joints on both sides of the body, and muscle pain and weakness. Skin problems are common in SLE. A characteristic feature is a flat red rash across the cheeks and bridge of the nose, called a &#x27;butterfly rash&#x27; because of its shape. The rash, which generally does not hurt or itch, often appears or becomes more pronounced when exposed to sunlight. Other skin problems that may occur in SLE include calcium deposits under the skin (calcinosis), damaged blood vessels (vasculitis) in the skin, and tiny red spots called petechiae. Petechiae are caused by a shortage of cells involved in clotting (platelets), which leads to bleeding under the skin. Affected individuals may also have hair loss (alopecia) and open sores (ulcerations) in the moist lining (mucosae) of the mouth, nose, or, less commonly, the genitals.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17368\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"autosomal-systemic-lupus-erythematosus-type-16","sourceDocuments":[{"name":"GARD: Autosomal systemic lupus erythematosus type 16","reviewed":null,"source_release":"2026-10-25T03:42:22Z","url":"https://rarediseases.info.nih.gov/diseases/17368"},{"name":"MONDO: autosomal systemic lupus erythematosus type 16","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0013743"}],"sourceNote":"","synonyms":["SLEB16","systemic lupus erythematosus 16","systemic lupus erythematosus related to DNASE1L3","systemic lupus erythematosus type 16"],"takeawayHtml":"","title":"autosomal systemic lupus erythematosus type 16"},"schemaVersion":1}
